Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
← catalyst calendarNCT06277037 · readout in 1,107 d
Sponsored by Arbutus Biopharma Corporation (industry) · ABUS — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
18
Countries
Australia, Hong Kong, Moldova +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-11 | actual | When the study began enrolling |
| Primary completion | 2029-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Long Term Follow-up
Intervention
- Other: Non-interventional
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the durability of effect of imdusiran on HBV parameters
measured Up to 96 weeks
To evaluate the durability of effect of imdusiran on HBV parameters
measured Up to 96 weeks
To evaluate the durability of effect of imdusiran on HBV parameters
measured Up to 96 weeks
Permalink · ABUS's whole pipeline · Catalyst calendar · Every registered study · What changed